Physicians will make their own decisions as to which patients might benefit most from biosimilars therapy.
Consider the following situation: the Food and Drug Administration (FDA) has approved biosimilar-xxyy (no matter for which disease).
The main questions of structural and molecular similarity have been answered by the FDA. The clinical trials for one indication show no clinically meaningful difference compared with the originator drug, and the FDA approves extrapolation to second indication for a different class of disorder.
Assuming the payer will make a decision to cover this agent on a preferred copayment tier for this self-administered biologic, physicians will now have to make their own decisions as to which patients might benefit most from therapy with this biosimilar, and in whom it might be safest, from their point of view, to start prescribing it.
We speak constantly today about overcoming barriers to physician uptake of new biosimilars. A large part of this involves education and information. Their sources of information on biosimilars will be only slightly different than the information pipeline for any biologic. The difference is that this is a biologic, and professional societies (and even patient groups) may have taken a stand to be extra cautious about its use.
Without pressure from payers to switch patients who are stable taking the originator product, it will then be a physician-based or patient-physician decision. Logically, this will be limited to patients who have not been treated with biologics in the past. For these patients, the risk of immunogenicity or adverse events is really no different than if they received the originator product for the first time. And a conversation will often take place with their colleagues about whether they had used the biosimilar, and was the outcome as intended.
However, another conversation that may well take place before prescribing is between the physician and the practice manager. The content of that discussion may be of an administrative nature, such as, “if I order this drug, will it be reimbursed without any problem?” In the case of a payer who has not yet held a Pharmacy & Therapeutics (P&T) Committee meeting to determine coverage, the same question may be asked but more urgently. “Do we even know what the patient copay may be? Do we have to acquire additional prior authorization approvals?” Additionally, the practice manager will wonder whether the biosimilar manufacturer has set up a “hub” to offer the payment and access assistance needed to smoothly order and deliver the product.
Ensuring the comfort of the practice manager is sometimes given too little consideration. This can go a long way to easing the physician into prescribing biosimilar-xxyy for that first patient.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.